acalabrutinib (Calquence)
Jump to navigation
Jump to search
Indications
- mantle cell lymphoma (breakthrough therapy designation)
- chronic lymphocytic leukemia
- small lymphocytic lymphoma
Dosage
Capsule & tablet
Mechanism of action
- Bruton tyrosine kinase inhibitor
- prevents activation of the B-cell antigen receptor signaling pathway[1]
More general terms
References
- ↑ 1.0 1.1 PubChem: 71226662
- ↑ 2.0 2.1 Bankhead C. OncoBreak: Terms of Life; FDA Approval Flurry; Gums and Cancer. News, features, and commentary about cancer-related issues MedPage Today. August 03, 2017 https://www.medpagetoday.com/PublicHealthPolicy/Ethics/67048
Windle ML. FDA New Drug and Biologic Approvals -- 2017 Year-in-Review Medscape - Jan 11, 2018. https://reference.medscape.com/viewarticle/890871
U.S. Food and Drug Administration. Novel Drug Approvals for 2017. https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DrugInnovation/ucm537040.htm - ↑ Wang M, Rule S, Zinzani PL et al Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial. Lancet. 2017 Dec 11. pii: S0140-6736(17)33108-2. [Epub ahead of print] PMID: https://www.ncbi.nlm.nih.gov/pubmed/29241979
- ↑ Otto MA FDA Approves Tablet Formulation of Acalabrutinib (Calquence) for CLL, SLL, and MCL. Medscape. Aug 5, 2022 https://www.medscape.com/viewarticle/978732